Hydroxypropyl-sulfobutyl-ß-cyclodextrin improves the oral bioavailability of edaravone by modulating drug efflux pump of enterocytes.

The objective of the study was to evaluate the effect of hydroxypropyl-sulfobutyl-ß-cyclodextrin (HP-SBE-ßCD) on the bioavailability and intestinal absorption of edaravone, and identify its mechanism of action. We devised HP-SBE-ßCD as a carrier and modulator of P-glycoprotein (Pgp) efflux pump, and edaravone as a model drug, and prepared edaravone/HP-SBE-ßCD inclusion complex. HP-SBE-ßCD improved the water solubility and enhanced the bioavailability of edaravone by 10.3-fold in rats. Then, in situ single-pass intestinal perfusion showed that HP-SBE-ßCD had an effect of improving the permeability and inhibiting the efflux of edaravone. Furthermore, the effects of HP-SBE-ßCD on Pgp were achieved through interfering with the lipid raft and depleting the cholesterol of enterocytes membrane. From the results, we presented the novel mechanisms. First, edaravone/HP-SBE-ßCD had a lower release from the inclusion compound to protect edaravone from the low pH of the stomach. Then, HP-SBE-ßCD modulated the membrane microenvironment of intestinal absorption epithelial cells. At last, the result was that HP-SBE-ßCD enhanced the absorption of edaravone by interfering with Pgp. In conclusion, HP-SBE-ßCD improves the bioavailability of drug not only because of its enhancing water solubility of the drug, but also because it modulates the Pgp-mediated efflux from enterocytes.